 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular TherapeutixTM, Inc. Nasdaq: OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of 75.0 million of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional 11.25 million of its common stock 